The tumor blood testing market size has grown rapidly in recent years. It will grow from $5.98 billion in 2025 to $6.78 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rise in cancer prevalence, limitations of tissue biopsy, advancements in genomic testing, oncology research funding, demand for non-invasive diagnostics.
The tumor blood testing market size is expected to see rapid growth in the next few years. It will grow to $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to early cancer screening programs, ai-enabled genomic analysis, personalized medicine growth, expansion of companion diagnostics, clinical trial adoption. Major trends in the forecast period include liquid biopsy adoption, multi-cancer early detection, minimal residual disease monitoring, personalized oncology testing, high-sensitivity biomarker detection.
The rising occurrence of cancer is expected to contribute to the growth of the tumor blood testing market in the near future. An aging population and increased exposure to risk factors such as unhealthy diets, tobacco use, and environmental pollution are leading to a higher number of cancer cases. This is creating greater demand for early detection methods. Tumor blood testing offers a less invasive approach for identifying cancer at an early stage by detecting specific biomarkers in the blood. This allows for earlier diagnosis, timely treatment, better patient outcomes, and continuous monitoring of disease progression as well as therapy effectiveness. For example, in May 2024, the National Cancer Institute, a government organization in the United States, reported that as of January 2022, an estimated 18.1 million cancer survivors were living in the country, with this number expected to grow to 26 million by 2040. As a result, the increasing number of cancer cases is contributing to the expansion of the tumor blood testing market.
Leading companies in the tumor blood testing market are prioritizing the development of new technologies, including non-invasive liquid biopsy techniques, to improve early cancer detection, monitor how patients respond to treatment, and track disease progression more effectively. These liquid biopsy methods are diagnostic tools that identify and examine cancer-related biomarkers found in body fluids, offering a safer and more convenient option compared to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a biotechnology company based in the United States, partnered with Immunocore Holdings plc, a biotechnology company based in the United Kingdom, to introduce the DELFI-Tumor Fraction assay. This blood test evaluates fragments of cell-free DNA present in the bloodstream to determine tumor levels and how the body is responding to treatment. This liquid biopsy, which relies on fragmentome analysis, serves as a non-invasive and cost-efficient alternative to conventional diagnostic procedures, requiring only a small amount of plasma and delivering results within two weeks.
In August 2025, Exact Sciences Corp., a diagnostics and biotechnology firm based in the United States, obtained the rights to a blood-based colon cancer screening test developed by Freenome Holdings Inc. for an undisclosed sum. With this acquisition, Exact Sciences Corp aims to strengthen its position in the field of early cancer detection and enhance its technological offerings by integrating Freenome Holdings Inc.'s advanced platform, which uses multiple types of data along with artificial intelligence to support blood testing. Freenome Holdings Inc. is a biotechnology company located in the United States that is focused on developing blood-based diagnostics to identify cancer at an early stage.
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor blood testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs for imported sequencing reagents, diagnostic kits, and analytical instruments used in tumor blood testing. North America and Asia-pacific are most affected due to dependence on specialized consumables. Diagnostic laboratories and research institutions face cost pressure, while tariffs are encouraging regional reagent manufacturing and localized testing infrastructure.
The tumor blood testing market research report is one of a series of new reports that provides tumor blood testing market statistics, including tumor blood testing industry global market size, regional shares, competitors with a tumor blood testing market share, detailed tumor blood testing market segments, market trends and opportunities, and any further data you may need to thrive in the tumor blood testing industry. This tumor blood testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tumor blood testing is a diagnostic technique that analyzes a blood sample to identify cancer-related biomarkers. It primarily detects genetic material released by tumors, such as circulating tumor DNA (ctDNA), providing a minimally invasive alternative to traditional tissue biopsies for cancer detection and monitoring. This approach enables earlier diagnosis, continuous disease monitoring, and more informed treatment decisions.
The primary types of tests in the tumor blood testing market include circulating tumor cell (CTC) tests, circulating tumor DNA (ctDNA) tests, exosome-based tests, and others. CTC tests detect and analyze cancer cells that have detached from a primary tumor and are circulating in the bloodstream. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray-based testing, mass spectrometry, and immunoassays. Tumor blood testing is applied to various cancers, including breast, colorectal, lung, prostate, and melanoma. Major applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Primary end-users comprise hospitals, diagnostic laboratories, research institutes, and other healthcare organizations.
The tumor blood testing market consists of revenues earned by entities by providing services such as liquid biopsy testing services, early cancer detection services, clinical trial support services, genetic mutation profiling services, and cancer biomarker screening services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor blood testing market also includes sales of exosome isolation kits, immunoassay kits, microfluidic devices, epigenetic assay kits, and protein biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The tumor blood testing market size is expected to see rapid growth in the next few years. It will grow to $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to early cancer screening programs, ai-enabled genomic analysis, personalized medicine growth, expansion of companion diagnostics, clinical trial adoption. Major trends in the forecast period include liquid biopsy adoption, multi-cancer early detection, minimal residual disease monitoring, personalized oncology testing, high-sensitivity biomarker detection.
The rising occurrence of cancer is expected to contribute to the growth of the tumor blood testing market in the near future. An aging population and increased exposure to risk factors such as unhealthy diets, tobacco use, and environmental pollution are leading to a higher number of cancer cases. This is creating greater demand for early detection methods. Tumor blood testing offers a less invasive approach for identifying cancer at an early stage by detecting specific biomarkers in the blood. This allows for earlier diagnosis, timely treatment, better patient outcomes, and continuous monitoring of disease progression as well as therapy effectiveness. For example, in May 2024, the National Cancer Institute, a government organization in the United States, reported that as of January 2022, an estimated 18.1 million cancer survivors were living in the country, with this number expected to grow to 26 million by 2040. As a result, the increasing number of cancer cases is contributing to the expansion of the tumor blood testing market.
Leading companies in the tumor blood testing market are prioritizing the development of new technologies, including non-invasive liquid biopsy techniques, to improve early cancer detection, monitor how patients respond to treatment, and track disease progression more effectively. These liquid biopsy methods are diagnostic tools that identify and examine cancer-related biomarkers found in body fluids, offering a safer and more convenient option compared to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a biotechnology company based in the United States, partnered with Immunocore Holdings plc, a biotechnology company based in the United Kingdom, to introduce the DELFI-Tumor Fraction assay. This blood test evaluates fragments of cell-free DNA present in the bloodstream to determine tumor levels and how the body is responding to treatment. This liquid biopsy, which relies on fragmentome analysis, serves as a non-invasive and cost-efficient alternative to conventional diagnostic procedures, requiring only a small amount of plasma and delivering results within two weeks.
In August 2025, Exact Sciences Corp., a diagnostics and biotechnology firm based in the United States, obtained the rights to a blood-based colon cancer screening test developed by Freenome Holdings Inc. for an undisclosed sum. With this acquisition, Exact Sciences Corp aims to strengthen its position in the field of early cancer detection and enhance its technological offerings by integrating Freenome Holdings Inc.'s advanced platform, which uses multiple types of data along with artificial intelligence to support blood testing. Freenome Holdings Inc. is a biotechnology company located in the United States that is focused on developing blood-based diagnostics to identify cancer at an early stage.
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor blood testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs for imported sequencing reagents, diagnostic kits, and analytical instruments used in tumor blood testing. North America and Asia-pacific are most affected due to dependence on specialized consumables. Diagnostic laboratories and research institutions face cost pressure, while tariffs are encouraging regional reagent manufacturing and localized testing infrastructure.
The tumor blood testing market research report is one of a series of new reports that provides tumor blood testing market statistics, including tumor blood testing industry global market size, regional shares, competitors with a tumor blood testing market share, detailed tumor blood testing market segments, market trends and opportunities, and any further data you may need to thrive in the tumor blood testing industry. This tumor blood testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tumor blood testing is a diagnostic technique that analyzes a blood sample to identify cancer-related biomarkers. It primarily detects genetic material released by tumors, such as circulating tumor DNA (ctDNA), providing a minimally invasive alternative to traditional tissue biopsies for cancer detection and monitoring. This approach enables earlier diagnosis, continuous disease monitoring, and more informed treatment decisions.
The primary types of tests in the tumor blood testing market include circulating tumor cell (CTC) tests, circulating tumor DNA (ctDNA) tests, exosome-based tests, and others. CTC tests detect and analyze cancer cells that have detached from a primary tumor and are circulating in the bloodstream. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray-based testing, mass spectrometry, and immunoassays. Tumor blood testing is applied to various cancers, including breast, colorectal, lung, prostate, and melanoma. Major applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Primary end-users comprise hospitals, diagnostic laboratories, research institutes, and other healthcare organizations.
The tumor blood testing market consists of revenues earned by entities by providing services such as liquid biopsy testing services, early cancer detection services, clinical trial support services, genetic mutation profiling services, and cancer biomarker screening services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor blood testing market also includes sales of exosome isolation kits, immunoassay kits, microfluidic devices, epigenetic assay kits, and protein biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Tumor Blood Testing Market Characteristics
3. Tumor Blood Testing Market Supply Chain Analysis
4. Global Tumor Blood Testing Market Trends and Strategies
5. Tumor Blood Testing Market Analysis of End Use Industries
7. Global Tumor Blood Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Tumor Blood Testing Total Addressable Market (TAM) Analysis for the Market
9. Tumor Blood Testing Market Segmentation
10. Tumor Blood Testing Market Regional and Country Analysis
11. Asia-Pacific Tumor Blood Testing Market
12. China Tumor Blood Testing Market
13. India Tumor Blood Testing Market
14. Japan Tumor Blood Testing Market
15. Australia Tumor Blood Testing Market
16. Indonesia Tumor Blood Testing Market
17. South Korea Tumor Blood Testing Market
18. Taiwan Tumor Blood Testing Market
19. South East Asia Tumor Blood Testing Market
20. Western Europe Tumor Blood Testing Market
21. UK Tumor Blood Testing Market
22. Germany Tumor Blood Testing Market
23. France Tumor Blood Testing Market
24. Italy Tumor Blood Testing Market
25. Spain Tumor Blood Testing Market
26. Eastern Europe Tumor Blood Testing Market
27. Russia Tumor Blood Testing Market
28. North America Tumor Blood Testing Market
29. USA Tumor Blood Testing Market
30. Canada Tumor Blood Testing Market
31. South America Tumor Blood Testing Market
32. Brazil Tumor Blood Testing Market
33. Middle East Tumor Blood Testing Market
34. Africa Tumor Blood Testing Market
36. Tumor Blood Testing Market Competitive Landscape and Company Profiles
37. Tumor Blood Testing Market Other Major and Innovative Companies
40. Tumor Blood Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Tumor Blood Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses tumor blood testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tumor blood testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor blood testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Circulating Tumor Cells (CTC) Tests; Circulating Tumor DNA (CtDNA) Tests; Exosome-Based Tests; Other Test Types2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing; Next-Generation Sequencing; Immunoassays
3) By Cancer Type: Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; Melanoma
4) By Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring
5) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End-Users
Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells; Enumeration Of Tumor Cells; Characterization Of Tumor Cells2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA; Methylation Analysis Of Tumor DNA; Copy Number Variation Analysis Of Tumor DNA; Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes; RNA Profiling Of Exosomes; Lipid Profiling Of Exosomes; Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests; Tumor Educated Platelet Tests; Protein Biomarker Panels; Multiomics Blood Tests; Immuno Oncology Biomarker Tests
Companies Mentioned: Bio-Techne Corporation; Roche Holding AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Natera Inc.; Myriad Genetics Inc.; Neogenomics Laboratories Inc.; Guardant Health Inc.; Foundation Medicine Inc.; Adaptive Biotechnologies Corporation; Freenome Holdings Inc.; Grail Inc.; Personal Genome Diagnostics Inc.; Exosome Diagnostics Inc.; Agena Bioscience Inc.; Menarini Silicon Biosystems S.p.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Tumor Blood Testing market report include:- Bio-Techne Corporation
- Roche Holding AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Siemens Healthineers AG
- Illumina Inc.
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- Natera Inc.
- Myriad Genetics Inc.
- Neogenomics Laboratories Inc.
- Guardant Health Inc.
- Foundation Medicine Inc.
- Adaptive Biotechnologies Corporation
- Freenome Holdings Inc.
- Grail Inc.
- Personal Genome Diagnostics Inc.
- Exosome Diagnostics Inc.
- Agena Bioscience Inc.
- Menarini Silicon Biosystems S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.78 Billion |
| Forecasted Market Value ( USD | $ 11.13 Billion |
| Compound Annual Growth Rate | 13.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
